25 May 2013
Keywords: vicuron, anti-fungal, superior, pfizer, results, phase, iii
Article | 14 February 2005
Results of a Phase III clinical trial have demonstrated that Vicuron Pharmaceuticals' anidulafungin appears superior in efficacy to fellow
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 February 2005
24 May 2013
© 2013 thepharmaletter.com